fbpx

Reforming FDA, not price control, is path to cheaper drugs

Guest Opinion//May 25, 2017//[read_meter]

Home>Commentary>

Reforming FDA, not price control, is path to cheaper drugs

Reforming FDA, not price control, is path to cheaper drugs

Guest Opinion//May 25, 2017//[read_meter]

Among the frustrations with our health care industry, reducing drug prescription costs is an issue that seems to unify all Americans. Unfortunately, politicians in Washington seemed fixated on solutions that...

Get 24/7 political news coverage and access to events honoring top political professionals

Tags: FDA, price controls, prescription drugs

Related Content

Have we truly come to celebrate violence?

The path forward demands courage, but it must be the courage to build, not destroy, to unite, not divide. If w[...]

December 20, 2024

Lawmakers, others must understand criminal code before trying to improve it

The key word in the phrase earned release credits is:  earned.  Prisoners must earn release credits in order[...]

December 20, 2024
vapes, disposable vapes, e-cigarettes, FDA

Illicit vape task force needs accountability for inaction

The FDA, DOJ and other agencies on the task force have so far failed to properly enforce their own laws or reg[...]

December 17, 2024

Organizers who mobilized voters can tell you why Harris lost Arizona

If Democrats want to win these voters back, they need to ...

December 13, 2024
death penalty, execution, killings

Dear President Biden: Leave us with an example of compassionate leadership

As a young person watching the results of the recent presidential election unfold, I’m concerned we’re ent[...]

December 10, 2024

Are legislators to blame for long vote counts?

If legislative leaders are really inspired to make positive progress that could actually result in new, pro-vo[...]

December 10, 2024

Subscribe

Get our free e-alerts & breaking news notifications!

Recent News

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.